Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guess is most trading over next month will be in $2.50 to $2.75 range
I wonder what institution on backstop, but top down the main body to success will be how much by end of August in this offering, $25 million by then would be bullish. Company after all does not have to have $46 million at this time. Maybe with building costs, we could argue and say $27 million before fees, and paying off costs with interim would be a better figure
500 to 1 is smart as well for offering blueprint, hope it is all not whistling in the wind. The plans for delcath future are not cheap, but as for spending rate I think delcath is much improved over the Royal King Hobbs and his days of glory. Optimal spending though, one should assume never. Certainly with money on hand IF, it is the question of when phase 3 ends that will be my concern
Management has got a struggle to piece all this together, it would take some convincing for me to alter 394 share stake until the crystal ball gets mighty clear
Why anybody puts up a lot of money on delcath will always be a mystery. They did. They voted YES. That means the chance of a hugely successful rights offering is a mystery. Without them though, ugh.
Say 50 little guys put up $10K on average, $500K would only be off 100 fold
Mgmt tends to always be on the verge of drowning, so what really objectively could people expect. It is self explanatory. There is only one path to a very successful rights deal. That would be if the quiet powerful Indian tribe which voted YES is alive and well.
Bottom line it is possible that this will be fully subscribed, it is better than trying to do another convertible. I would be much more optimistic if this had been initiated by late May, lay your bets
It is reasonable to suspect something, eventually this puppy will enter another phase as we continue in purgatory
Hindsight is next to Godliness, I think no conservative little investor should be greedy at this time
No BK is not a good option, if the technology is financially attractive, b/o or partnership but really the earlier in time the better, I think management would know that as I suspect rights offering is perceived from above as a wild hail mary pass. Thus this offering affirms there is no interest in the technology, world is just too skeptical of revenue potential, 394 shares not a biggie
The filing is fairly good news so I will hold 394 shares at $2.74, but I don't think I will exercise the rights.
Prior to backstop I believe $25 million must be raised for an actually bullish signal. $15 million would easily be good news, but sticks the price close to $1.75 imo
Assuming for the moment no news, I find it shocking to close at $2.74, I need to wake up and try to sell 394 shares at a good price, if a little more gas left in price structure
The continuing shortage of money leads me to believe enrollment is still creeping so I suspect chances of end of phase 3 remain low until early 2019, then maybe a transition to if 100 fully treated in the 2 arms combined with adequate time of maturity may accelerate
I disagree strongly, it was holders of stock fearing for their lives based on their technical read of last reverse split. More savvy folks than I anticipated there was seller exhaustion to capitalize on
I am sticking to my own view without researching parallels. Certain things could be changed but the 2 biggies to negate the criticism: 1) big financing deal 2) very nice icing would be company insiders jump in on the financing or right after the financing
It will be a miracle in that case, yes or no? But I think it wrong, wrong, wrong, WRONG to believe Simpson wants less than success in the end
I am not an authority of any kind on the world of shorting. I don't believe delcath though is a shorting story at all. Indeed it is a lack of investor interest story which is very serious because the most likely outcome is poor rather inadequate financing or no financing and a possibly quick end here.
Good financing equates to deity status here
Sorry but the dismissive slap has to be challenged. The company put out the best press release it was capable of this week with 100 treatments cumulative for a 3rd site.
Simpson will be a Goddess if she snatches victory from the jaws of defeat. I may hang on to my measly 394 shares to the bitter end
I have not, but nothing with save a cost basis developed before Dec of last year.
I would not totally rule out after all the wrong assertions on a buyout or partnership, I just would not count on such but it is nice that such confidence posts have dropped away. Thus we all can be on the same page that there is no blessed assurance or even expectation
When in doubt, doubt the positive. Keeping the real negative on the straight and narrow, excessively confusing writings stink as salt but the wound is all financings since start of 2016 have been subpar at best.
You made an assertion but without the coloring of detail to prove it. I will as well believe Simpson on listing nor did delisting cause the massive collapse, etc. The history is never going to be straight here, that is a sure fact
Pre approval revenue still matters logically. If this company gets approved and revenue is still no better than $3 million annual, one could be very critical about potential. Thinking forward immediately, delcath should be judged on one thing, getting money.
With money in the bank if blessed, then revenue matters, enrollment pace matters even more
I consider investor history one of delusion. I have been there on this as well. We could not stay on Nasdaq and it is not a big deal. Imo if the big boys fork over massive money, Nasdaq is likely coming again. I am not sure listing matters until and if this was to be heavily owned by institutions. I rate low revenue as probably more of a problem, sure hope that 2018 easily surpasses 2017
It is surprising that the stock price has held up as well as it has. I remain in a position of about 400 shares, don't wish to lose more than my little toenail
After so many stated, I found the statement was made that it could allow for remaining on Nasdaq, reverse splits are always the correct thing to do, fact as far as I am concerned. Indeed to vote NO is to abandon fiduciary duty as owners of an equity. First fiduciary duty though is aways to know when to buy, sell, hold, etc..
If big money is interested, a gigantic ratio would be like gentle rain, if they are not interested I fear ratios are futile
I believe tickerpicker has described conditions best. Delcath has a team of real competitors going for FDA approval but have been on the verge of drowning. When push comes to shove, they will pull foolish money under in an attempt to stay alive. The only way to suddenly end this situation appears to be to raise substantial money in one deal. I am very skeptical right now that this deal will be great, but I am all for it if truly going for some good money here
There need to be pointers towards revenue, but right now it is about judgement of big money
Revenue, we would all like to forget about with European history
I am extremely skeptical that qualified business people would want to have anything to do with delcath for its whole history.
If the company gets $45 million, Simpson is fine for her role imo for a few more months. Possibly a change before U.S. approval would make sense
After all $30 million needs to be achieved in revenue and probably surpassed bigly
I think that is mostly a wrong view as phase 3 has made progress and chemosat has to be worthy of getting the phase 3 completed. Your views over the past fews days are super contradictory as mid-week you believed about $45 million would be raised. If you highly doubt a $45 million cash in the bank happens, unfortunately I am with you
What no long likes to think about though is chemosat may not be worthy of spending money on. Probably needs to reach at least about $30 million revenue annually and that is no done deal
reverse split last done is now a super positive except for money has to come. Mathematically this is perfectly setup for a great way to speculate, all possibilities from bankruptcy to dilution killing in steps the potential or finding A pretty powerful floor
Money in the bank is the only great hope during next few months imo, excepting money in the bank might mean an additional huge catalyst of getting on Nasdaq
I believe it may come down to big money either likes the company as is OR does not. I would view as how many dollars will it take to reach $300 million market cap. If I had $10 billion in the bank, I would finance this puppy
The underlying problem is to raise a lot of cash at once and of course without any variable component. This allows speculation with confidence that there is no foundation for constant selling of shares to raise cash. Shooting for $50 million in print is great, but the sword is mightier than the pen
I have never researched as to what percentage of companies that go bankrupt yield good cash to common shareholders, but I suspect very low caps very rarely yield a single penny and if they do, you might have to wait 10 years.
Primarily because people have decided Simpson is the worst of the worst, they embrace bankruptcy, b/o talk, anything.
I think company had its best shot to turn the corner in May but could not put something together. Unless a filing knocks my socks off, I will not embrace any rights offered to me
Is there anything more than hunches about how raising money will go? If so, I am missing the clues. Of course that means all filings on such topic imo equate to hunches
maybe one treatment excluding cost of filter, $50,000 for operating team, room, and one night in hospital. With filter if $25,000, total cost $75,000
I think the company would be ecstatic to get 10 percent of European revenue for right to try, how many treatments is that - about 10 or so, theoretically one wealthy patient perhaps. How much would 10 treatments cost including hospital costs etc.., half million?
You are the one true bull, if any imo, let's see the next filing
I can What IF with the best of them, is she a Goddess in the rough, err too rough?